FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Clinical trials should be starting at Harvard's Dana-Farber Cancer Center in the next two months as Cellceutix looks to validate their laboratory research on Kevetrin, their novel drug in development for the treatment of drug resistant cancers. Yesterday, it was disclosed that Syracuse basketball icon Jim Boeheim has come on board the Cellceutix team in the fight against cancer.

Weekly roundup of stocks moving in and out of Joel Greenblatt's Magic Formula Investing screens.

Tickers:
ABC | ADI | AFAM | AMAT | AMED | AVEO | CACI | DAR | DEXO | DLX | DNB | GD | HRB | ICON | IDCC | LLY | LPS | MCK | MD | MHP | MKSI | NOC | ORCL | STRA | TRW | UIS | USNA | WSTG | XLS
Tags:
Investment Ideas, LLY, NOC, gd, ORCL, hrb, ICON, magic formula investing, ABC, lps, MHP, AFAM, amat, STRA, UIS, DNB, DAR, IDCC, MCK, AMED, MD, DLX, DEXO, usna, WSTG, AVEO, CACI, TRW, ADI, MKSI, XLS

Weekly roundup of stocks moving in and out of Joel Greenblatt's Magic Formula® Investing screens.

Strange Volume of Eli Lilly - NYSE:LLY

Posted by akki on February 10th, 2012

Eli Lilly & Co (NYSE:LLY) discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. Eli Lilly & Co witnessed volume of 31.14 million shares during last trade however it holds an average trading capacity of 7.68 million shares.

Tickers:
LLY
Tags:
, LLY, NYSE:LLY, Eli Lilly

Eli Lilly & Co (NYSE:LLY) discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. Eli Lilly & Co witnessed volume of 26.02 million shares during last trade however it holds an average trading capacity of 7.36 million shares.

Weekly roundup of stocks moving in and out of Joel Greenblatt's Magic Formula® Investing screens.

Weekly roundup of stocks moving in and out of Joel Greenblatt's Magic Formula® Investing screens.

Cellceutix Corporation (OTCBB:CTIX) has regularly reported significant breakthroughs in cancer research through studies of Kevetrin, the company’s novel cancer drug in development. Amazing data has been collected by Cellceutix researchers testing Kevetrin against many cancer lines, including head & neck, prostate, lung, colon, pancreatic and leukemia.

Eli Lilly & Co with Positive Gains - NYSE:LLY

Posted by akki on January 4th, 2012

Eli Lilly & Co (NYSE:LLY) discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. Eli Lilly & Co achieved its new price of $42.03 where it was opened at $41.95 up 0.24 points or +0.58% by closing at $41.80.

Eli Lilly & Co Stocks Ended in Red - NYSE:LLY

Posted by akki on December 23rd, 2011

Eli Lilly & Co. (NYSE:LLY) Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. Eli Lilly & Co. achieved its new 52 week high price of $41.86 where it was opened at $41.77 down -0.11 points or -0.26% by closing at $41.46.

ReneSola Ltd. (NYSE:SOL) a leading global manufacturer of solar products, announced the completion and grid connection of the Company's 20 megawatt ("MW") solar power plant in Wulan County in Qinghai, China with the Company providing all 20 MW of solar modules. The solar power plant is the first of its kind for ReneSola.

Pages